The present invention relates generally to a screening module and the method for operating the same, and particularly to a screening module capable of screening prostate cancer rapidly and the method for operating the same.
A prostate cancer comes from malignant tumors in the prostate. If gene mutation occurs and results in loss of control in proliferation, it becomes a cancer. In addition to expansion in volume or encroachment to neighboring organs, malignant cells can possibly transfer to other parts of the body, in particular bones and lymph nodes. A prostate cancer can lead to pains, impaired urinary elimination, or erection dysfunction.
A prostate cancer is mostly discovered during regular health examinations or blood screening. There are still doubts on the accuracy and effect of the prostatic specific antigen (PSA). Nonetheless, it remains the screening tool adopted most extensively for prostate cancers. In generally, when a suspect prostate cancer case is discovered, the biopsy is performed for validating a diagnosis. Other further examinations, such as X-ray scans, computerized tomography scans, and bond scans, can facilitate understanding if the prostate cancer has spread.
Unfortunately, the biopsy is after all an invasive examination. Besides, the examination is not immediate. Accordingly, in order to enhance the efficiency of screening prostate cancer, other methods should be sought as auxiliaries.
According to the current technology, scientists have found that sarcosine can be used as the biologic indicator for screening prostate cancer. Nonetheless, how to find the content of sarcosine in a sample rapidly and conveniently is still to be developed. The present invention provides a non-invasive method for screening rapidly and conveniently.
An objective of the present invention is to provide a prostate cancer screening module and the method for operating the same. By using the principle that the surface potential of the material of a sensing film (e.g. NiOx), varies by contacting hydrogen peroxide having different concentrations, the concentration of hydrogen peroxide can be judged by detecting voltage change. Then the content of sarcosine can be judged according to the concentration of hydrogen peroxide.
Another objective of the present invention is to provide a prostate cancer screening module and the method for operating the same. The sample under test is urine or blood serum. If the urine or blood serum contains sarcosine, hydrogen peroxide will be produced after oxidation. Then the produced hydrogen peroxide can be used to react with nickel oxide.
Still another objective of the present invention is to provide a prostate cancer screening module and the method for operating the same. Once the urine or blood serum sample contains traces of sarcosine, the voltage change owing to the change in the surface potential of the sensing film can be detected, leading to high sensitivity to sarcosine. The content of sarcosine in urine or blood serum is a factor for judging prostate cancer. Thereby, the present invention can be applied to screening prostate cancer.
A further objective of the present invention is to provide a prostate cancer screening module and the method for operating the same. The structure of the present invention is succinct and can be popularized as commercial screening chips. Thereby, screening for prostate cancer can become convenient and the result can be given immediately.
Accordingly, the present invention discloses a prostate cancer screening module, which comprises a conductive substrate, a p-type silicon semiconductor layer, a silicon dioxide layer, a sensing film, and a reference electrode. The p-type silicon semiconductor layer is disposed on the conductive substrate. The silicon dioxide layer is disposed on the p-type silicon semiconductor layer. The sensing film is disposed on the silicon dioxide layer for carrying a sample. The reference electrode is located above the sensing film for contacting the sample. Wherein the material of the sensing film is selected from the group consisting of NiOx, IrOx, GdOx, Pt, WOx, Si, Ge, Os, Pd, CrOx, CeOx, TaOx, ErOx, YOx, HfOx, ZrOx, SnOx, PrOx, SmOx, NbOx, ZnOx, LuOx, RuOx, MoS2Ox, TmOx, HoOx, DyOx, YbOx, EuOx, TbOx, IGZOx, InNOx, NdOx, Al, Ti, and graphene oxide.
The method for operating the above prostate cancer screening module comprises steps of: using a reference electrode to approach a sensing film and giving a first voltage; disposing a sample between the reference electrode and the sensing film, giving a second voltage, and the sample being urine or blood serum; and comparing the first voltage and the second voltage for giving a difference value, and using the difference value to judge the content of sarcosine in the sample.
In order to make the structure and characteristics as well as the effectiveness of the present invention to be further understood and recognized, the detailed description of the present invention is provided as follows along with embodiments and accompanying figures.
Please first refer to
In the structure according to the above preferred embodiment, the conductive substrate 1 is a copper-plated printed circuit board and can be used as an electrode corresponding to the reference electrode 5. The p-type silicon semiconductor layer 2 and the silicon dioxide layer 3 above the conductive substrate 1 enable the present invention to own the characteristics of an electrolyte-insulator-semiconductor sensor. The fabrication method for the structure is similar to normal semiconductor processes. By using chemical vapor deposition (CVD), plasma-enhanced CVD (PECVD), vapor deposition, e-gun vapor deposition, and radio-frequency (RF) sputtering, layers of different materials can be stacked. In order to increase electrical conductivity, according to a preferred embodiment, an aluminum electrode layer 6 is further included between the p-type silicon semiconductor layer 2 and the conductive substrate 1. Silver-silver chloride or other reference electrodes having a fixed potential difference can be selected to be the reference electrode 5.
According to a preferred embodiment, the sensing film 4 made by NiOx does not cover completely the silicon dioxide layer 3 in a thick film manner. Instead, nickel oxide is distributed on the silicon dioxide layer 4 in the form of nanometer particles. The thickness of the film is 1 to 5 nanometers and preferably 2 nanometers. According to another embodiment, titanium-oxide nanometer particles are further used to form a titanium oxide film. Nonetheless, the present invention is not limited to the use of titanium-oxide nanometer particles only to form the film. The titanium oxide film can be disposed below the sensing film 4. Alternatively, sputtering can be adopted to mix nickel-oxide nanometer particles and titanium-oxide nanometer particles and form the film. In other words, the titanium film and the sensing film 4 are disposed on the silicon dioxide layer 3 in a mixed fashion. According to still another preferred embodiment, after preparation of the titanium oxide film, a 650° C. annealing process can be performed for 30 minutes in ambient oxygen.
Please refer to
In addition, the prostate cancer screening module can further comprise a housing 8 formed by epoxy resin. The housing 8 can protect the layers inside from pollution or oxidation and thus extending the lifetime of the prostate cancer screening module.
As described above, when the structure disclosed in the present invention is operating, the liquid sampled is dripped on the surface of the sensing film 4. According to a preferred embodiment of the present invention, the gradient of the sample is urine. Presently, it is known the content of sarcosine in urine is closely related to the screening of prostate cancer. Accordingly, the present invention makes use of chemical reactions to detect C-V (capacitance-to-voltage) changes and hence judging if the urine or blood serum contains sarcosine.
The sample used in the present invention is urine or blood serum. If the urine contains sarcosine, the following reaction will occur:
After oxidation, the sarcosine in urine produces hydrogen peroxide. Namely, if hydrogen peroxide exists in the sample, it implies existence of sarcosine in the urine. If the concentration of hydrogen peroxide is higher, then the content of sarcosine is greater, meaning that the characteristics of prostate cancer are more apparent. Sarcosine oxidase (SOD) can be added to the sample in the above oxidation reaction and acting as the catalyst. In order to make sure the existence and the concentrate of hydrogen peroxide, according to the present invention, the sample contacts the sensing film. When nickel oxide contacts hydrogen peroxide, the following reduction reactions occur:
NiO+OH−→NiOOH (2)
2NiOOH+H2O2→2NiO+2H2O+O2 (3)
In Formula (2), nickel oxide produces nickel oxyhydroxide in alkaline ambience. Then, in Formula (3), the oxyhydroxide further reacts with hydrogen peroxide and is reduced to nickel oxide. The oxidation number of nickel is changed from +2 to +3. Besides, the potential is changed and thereby the screening module as described above can be used to detect changes in voltage. Consequently, the content of sarcosine in urine can be judged sensitively and real-timely for evaluating if a prostate cancer occurs.
Please refer to
Please refer to
Please refer to
Besides, while applying the present invention, a buffer solution can be further added between the sensing film and the reference electrode. The function of this buffer solution is to influence the pH value of the sample and thus adjusting the substrate bias.
To sum up, the present invention discloses in detail a prostate cancer screening module and the method for operating the same. The sample for detection is urine or blood serum. If the urine or blood serum contains elevated level of sarcosine, which is relevant to the prostate cancer, the sarcosine can be oxidized to produce hydrogen peroxide by reacting with an enzyme sarcosine oxidase. Then a sensing film made of nickel oxide can be used to react with the hydrogen peroxide and changing the surface of the sensing film. By detecting the voltage changes, the concentration of the hydrogen peroxide can be judged and hence deducing the content of sarcosine in the sample. The present invention owns the feature of rapid screening and high sensitivity. Accordingly, it is undoubtedly an extremely valuable prostate cancer screening module and the method for operating the same.
Accordingly, the present invention conforms to the legal requirements owing to its novelty, nonobviousness, and utility. However, the foregoing description is only embodiments of the present invention, not used to limit the scope and range of the present invention. Those equivalent changes or modifications made according to the shape, structure, feature, or spirit described in the claims of the present invention are included in the appended claims of the present invention.